phrykt

Sana Biotechnology, Inc. (SANA): who owns it and who trades it

As of Nov 16, 2026, no open-market insider purchases or sales of SANA were reported in the last 12 months. 5 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Sana Biotechnology

From the latest filings

Overall: about as much buying as selling. Famous investors mostly bought. Funds was close to even.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns SANA

210 funds and institutions reported SANA shares worth $649M at the end of Q2 2026, about 67% of the company. The largest holder is FMR LLC (Fidelity) with 13.4%.

Funds and institutions (13F) 67%Everyone else 33%

10 largest owners, by share of the company

FMR LLC (Fidelity)13.4%
Flagship Pioneering, LLC9.0%
Ra Capital Management, L.P.6.7%
BlackRock, Inc.6.0%
State Street Corp4.0%
Canada Pension Plan Investment Board3.7%
Vanguard Capital Management LLC3.0%
Bank of America Corp2.1%
Geode Capital Management, LLC1.7%
Marex Group Ltd1.4%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
FMR LLC (Fidelity)37.43M13.45%$131MNo change
Flagship Pioneering, LLC25.00M8.98%$87.3MNo change
Ra Capital Management, L.P.18.75M6.74%$65.4M–
BlackRock, Inc.16.68M5.99%$58.2M+17%
State Street Corp11.20M4.03%$39.1M+6%
Canada Pension Plan Investment Board10.22M3.67%$35.7MNo change
Vanguard Capital Management LLC8.38M3.01%$29.2M+13%
Bank of America Corp5.75M2.07%$20.1M+95%
Geode Capital Management, LLC4.68M1.68%$16.3M+12%
Marex Group Ltd3.99M1.43%$13.9M-0%
Marshall Wace, LLP2.93M1.05%$10.2M+341%
Alphabet Inc.2.81M1.01%$9.8MNo change
Goldman Sachs Group Inc2.37M0.85%$8.3M-26%
Integral Health Asset Management, LLC2.00M0.72%$7M-38%
Toronto Dominion Bank1.97M0.71%$6.9M–
Vanguard Portfolio Management LLC1.88M0.68%$6.6M+10%
Jacobs Levy Equity Management, Inc1.87M0.67%$6.5M–
Northern Trust Corp1.60M0.58%$5.6M+8%
Charles Schwab Investment Management Inc1.38M0.50%$4.8M+1%
Sixth Street Partners Management Company, L.P.1.38M0.50%$4.8M–

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

No SANA insider reported an open-market purchase or sale in the last 12 months.

Purchases, 12 months
$0
0 trades, 0 people
Sales, 12 months
$0
0 trades, 0 people
Sales under a 10b5-1 plan
–
Share of sale value
Latest trade
–
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

SANA short interest

High short interest. 13.5% of SANA shares are sold short: about 1 share in 7. Over the last 12 reports the number of shares short went up 6%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 40.60M SANA shares were sold short, 13.5% of the shares outstanding, down 0.6% from the report before. At the average daily volume of 2.57M shares, buying them all back would take about 15.8 trading days (days to cover).

Shares short, % of all shares

13.5%May 15Oct 3015.5%

Days to cover

15.8May 15Oct 3019.4

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 202640.60M13.55%-1%2.57M15.8
Oct 15, 202640.85M13.64%+5%3.72M11.0
Sep 30, 202638.73M12.94%-6%4.32M9.0
Sep 15, 202641.37M13.82%-0%3.39M12.2
Aug 31, 202641.56M13.88%-2%2.58M16.1
Aug 14, 202642.57M14.22%+1%2.37M18.0
Jul 31, 202642.15M15.15%+6%2.58M16.3
Jul 15, 202639.74M14.28%+3%3.01M13.2
Jun 30, 202638.70M13.91%-5%4.24M9.1
Jun 15, 202640.67M14.62%+3%3.68M11.1
May 29, 202639.33M14.13%+2%3.79M10.4
May 15, 202638.47M13.82%-6%4.51M8.5

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Sana Biotechnology company events

Sana Biotechnology filed 11 reports on Form 8-K in the last 12 months, 2 of them about an important change (leadership). The latest was on Nov 5, 2026.

  1. Nov 5, 2026ResultsReleased financial results. Filing
  2. Sep 8, 2026AnnouncementShared information with investors. Filing
  3. Aug 10, 2026ResultsReleased financial results. Filing
  4. Jun 5, 2026VoteReported shareholder vote results. Filing
  5. May 15, 2026AnnouncementSana Biotechnology, Inc. announced that it had sold an aggregate of 21,607,878 shares of its common stock, for aggregate net proceeds of approximately $69.0 million, pursuant to its amended and restated sales agreement with TD Securities (USA) LLC, acting as sales agent. 1 SIGNATURES Pursuant to… Filing
  6. May 11, 2026ResultsReleased financial results. Filing
  7. Apr 24, 2026LeadershipIn order to achieve a more equal balance of director membership among the three classes of the Board of Directors of Sana Biotechnology, Inc. in accordance with the Company’s Amended and Restated Certificate of Incorporation, the Board determined that one of its Class I directors (with a term… Filing
  8. Apr 13, 2026AnnouncementSana Biotechnology, Inc. entered into a stock purchase agreement with Mayo Clinic, pursuant to which the Company agreed to sell to Mayo Clinic, and Mayo Clinic agreed to purchase from the Company, (i) 7,507,507 shares of the Company’s common stock, $0.0001 par value per share, at a price of $3.33… Filing
  9. Mar 3, 2026AnnouncementThe Company entered into an amended and restated sales agreement with TD Securities (USA) LLC to sell shares of the Company’s common stock, $0.0001 par value per share, from time to time, through an “at the market offering” program under which TD Cowen will act as sales agent. Filing
  10. Feb 17, 2026LeadershipSana Biotechnology, Inc. announced that Brian Piper, M.B.A., joined the Company as Executive Vice President, Chief Financial Officer on February 17, 2026, and in such capacity, will serve as the Company’s Treasurer and Principal Financial Officer. Filing
  11. Jan 14, 2026AnnouncementShared information with investors. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Sana Biotechnology financials

Famous investors that hold SANA

5 of the 50 well-known investors we track reported holding SANA in their latest 13F filing. The largest position is Jim Simons's, worth $4.1M.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Jim Simons · Renaissance TechnologiesQ3 20261.42M$4.1M0.0%+15%
Ken Griffin · Citadel AdvisorsQ3 20261.20M$3.5M0.0%+642%
Israel Englander · Millennium ManagementQ3 2026389,728$1.1M0.0%-40%
Steve Cohen · Point72 Asset ManagementQ3 2026252,908$737K0.0%-58%
Paul Tudor Jones · Tudor Investment CorpQ3 2026149,679$436K0.0%+70%

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 2 filings named SANA in the last 120 days.

FiledHolderFormStake
Nov 5, 2026FMR LLC13G/A12.5%
Nov 5, 2026FMR LLC13G/A12.5%

Questions about Sana Biotechnology, Inc. (SANA) stock

Who owns the most SANA stock?

The largest reported owner of Sana Biotechnology, Inc. (SANA) is FMR LLC (Fidelity), with 13.4% of the company. In total, 210 funds and institutions reported holding SANA at the end of Q2 2026, together about 67% of the shares. See the largest owners.

Are SANA insiders buying or selling?

No SANA insider reported an open-market purchase or sale on Form 4 in the last 12 months. Share awards, option exercises and gifts are not counted.

What is the short interest in SANA?

As of Oct 30, 2026, 40.60M SANA shares were sold short, 13.5% of the shares outstanding, down 0.6% from the report before. At the average daily volume of 2.57M shares, buying them all back would take about 15.8 trading days (days to cover). See the history.

Which famous investors hold SANA?

5 of the 50 well-known investors we track reported SANA in their latest 13F filing, including Jim Simons, Ken Griffin, Israel Englander. The largest position is worth $4.1M. See all holders.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.